Komori
Human Metabolome Technologies (6090) · InitiativeAdvanced

Launch of a Comprehensive Support Service for Functional Materials Development and Establishment of a Business Foundation

First written in FY2023. 9 of 10 entries say "Advanced", first in FY2024-Q1. Latest entry: FY2026.

10entries
4years
2from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseAdvancedFY2024-Q1 – FY20262023: 220232024: 320242025: 120252026: 42026
Same theme, other companies
Commercialisation of a functional ingredient development support serviceA theme 1 companies write about · 0 as a headwind · 1 as a tailwind

No other company in this theme has enough history to compare yet.

Full recordFilings, disclosures and news, newest first
  1. FY2026AdvancedAnnual report

    「The functional material development support service also increased revenue to ¥363.885 million, up 16.6% from the previous consolidated fiscal year, as orders for health-claim measurement packages and other services remained strong.」

    Following the launch of the comprehensive support service for functional material development, orders for health-claim measurement packages and other services increased, driving a 16.6% year-on-year increase in service revenue.
  2. FY2026-H1AdvancedAnnual report

    「Functional material development support service; ¥167.830 million; 7.1%」

    Revenue from the functional material development support service increased 7.1%, from ¥156.680 million in the same period of the previous year to ¥167.830 million, due to revenue recognized in connection with a large-scale clinical trial.
  3. FY2025-H1AdvancedAnnual report

    「In this business segment, revenue from the service increased as the company focused on securing new orders for its functional material development support service. Revenue from skin gas measurement also increased.」

    The company pursued new orders for the comprehensive support service for functional material development launched in July 2023, leading to higher revenue.
  4. FY2024AdvancedAnnual report

    「Revenue increased substantially following the expansion of sales of the comprehensive support service for functional material development and the receipt of a large paid joint development project related to functional materials, among other factors.」

    The comprehensive support service for functional material development progressed to the stage of securing large paid joint development projects, contributing ¥158.818 million in annual revenue and ¥236.246 million in orders to the healthcare solutions business.
  5. FY2024-Q3AdvancedAnnual report

    「In this business segment, revenue increased substantially, partly because the company secured a large paid joint development project related to functional materials. Revenue from skin gas measurement and other services also remained firm. In R&D, the company worked on additional development of the comprehensive support service for functional material development and other services.」

    While advancing additional development of the comprehensive support service for functional material development and other services, the company progressed to the stage of securing large paid joint development projects.
  6. FY2024-Q2AdvancedAnnual report

    「In this business segment, revenue increased substantially as the company secured a large paid joint development project related to functional materials. Revenue from skin gas measurement and other services also remained firm. In R&D, the company worked on additional development of the comprehensive support service for functional material development and other services, while promoting the joint development of mental health biomarkers.」

    The company worked on additional development of the comprehensive support service for functional material development and other services, reaching the stage of securing large paid joint development projects.
  7. FY2024-Q1AdvancedAnnual report

    「In this business segment, we worked to increase orders for and pursue additional development of comprehensive support services for functional-materials development, while promoting business alliances for new services and the joint development of mental-health biomarkers.」

    Since launching the comprehensive support service for functional material development in July 2023, the company has made progress in expanding orders and adding development capabilities, while also promoting business alliances for the new service.
  8. FY2023First statedAnnual report

    「As a result, the company launched a one-stop solution service for functional material development, the comprehensive support service for functional material development, in July 2023.」

    The company launched a new service in July 2023 that comprehensively supports the search for relevant ingredients and acquisition of scientific evidence in functional material development.
Moved together

"Healthcare Solutions Business: ¥100 million in sales and segment profitability in five years" moved the same way as this thread, in the same document, in 7 of its 10 moves.

764444★123456
  1. ★This thread
  2. 1Healthcare Solutions Business: ¥100 million in sales and segment profitability in five years7×
  3. 2Capital investment to expand analytical capabilities and accelerate research and development6×
  4. 3Productivity Improvement in Analytical Work4×
  5. 4Policy of prioritizing retained earnings and considering future dividends4×
  6. 5Biomanufacturing Productivity Improvement Support Service4×
  7. 6Upfront investment phase of the depression biomarker business4×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
No upcoming earnings preview for Human Metabolome Technologies yet. It last moved in the Financial Results Presentation of 2026-08-20: "Advanced".
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Launch of a Comprehensive Support Service for Functional Materials Development and Establishment of a Business Foundation | Human Metabolome Technologies,Inc. (6090) | Komori